Lung Cancer Case Based Discussion Stage III Case-based Approach
This activity present on the the topic of: Lung SABR for early stage NSCLC, reviewing patient selection, treatment planning, dose-fractionation followed by challenging aspects such as ultra-central lesions and reirradiation, and Locally advanced (Stage III NSCLC), discussing patient selection for curative intent treatment, CT simulation, treatment planning for tumors close to critical structures, review of contemporary data.
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses, dosimetrists and radiation therapists.
Upon completion of this activity, participants should be able to do the following:
- Explain best practice in the use of stereotactic ablative body radiation for treatment of early stage lung cancer; analyze how to approach challenging situations such as central tumors
- Discuss contemporary radiation approaches in the treatment of stage III NSCLC; determine how to approach tumors in close proximity to critical structures.
- Identify optimal patient selection and treatment planning techniques for challenging scenarios for SABR.
- Apply latest data regarding treatment of locally advanced NSCLC.
Anand Shivnani, MD is employed at Texas Oncology, McKinney, TX, and has an investment interest from Gradalis.
Aileen Chen, MD is employed at the Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX and has no financial relationships with a commercial interest.
Florence K. Keane, MD is employed at Harvard Medical School, Boston, MA, and receives compensation from AstraZeneca, Merck, Siemens and OncLive.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.